Mackay Shields LLC’s Myriad Genetics MYGN Stock Holding History

Mackay Shields LLC’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-60,931	Closed	-$1.86M	–	1098
2021 Q1	$1.86M	Sell	60,931 -41,713	-41%	-$1.18M	0.01%	805
2020 Q4	$2.03M	Sell	102,644 -18,700	-15%	-$302K	0.01%	849
2020 Q3	$1.58M	Buy	121,344 +50,200	+71%	+$635K	0.01%	881
2020 Q2	$807K	Buy	71,144 +15,000	+27%	+$213K	0.01%	1088
2020 Q1	$803K	Buy	56,144 +3,400	+6%	+$71.8K	0.01%	1016
2019 Q4	$1.44M	Sell	52,744 -4,500	-8%	-$124K	0.01%	982
2019 Q3	$1.64M	Sell	57,244 -3,200	-5%	-$93.2K	0.01%	979
2019 Q2	$1.68M	Buy	60,444 +39,013	+182%	+$1.1M	0.01%	969
2019 Q1	$712K	Buy	21,431 +700	+3%	+$21.3K	0.01%	1094
2018 Q4	$602K	Sell	20,731 -1,071	-5%	-$38.5K	﹤0.01%	1096
2018 Q3	$1M	Sell	21,802 -2,300	-10%	-$102K	0.01%	877
2018 Q2	$901K	Sell	24,102 -500	-2%	-$16.9K	0.01%	982
2018 Q1	$727K	Buy	+24,602	New	+$832K	﹤0.01%	1059

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Mackay Shields LLC's MYGN Position: Q2 2021 in Review

Mackay Shields LLC sold out of Myriad Genetics (MYGN) in Q2 2021, closing a stake of 60,931 shares — an estimated $1.86M sold.

Mackay Shields LLC first reported a position in MYGN in Q1 2018 and held it in 13 quarters. The position peaked at $2.03M in Q4 2020. 201 funds tracked by Wall St. Rank hold MYGN as of Q2 2021.

Mackay Shields LLC reported no remaining Myriad Genetics position as of Q2 2021 after selling out during the quarter.
Mackay Shields LLC sold 60,931 Myriad Genetics shares in Q2 2021, an estimated $1.86M.
Mackay Shields LLC first reported a position in Myriad Genetics in Q1 2018 and held it in 13 quarters.
Mackay Shields LLC's Myriad Genetics position peaked at $2.03M in Q4 2020.
201 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2021.

Based on Mackay Shields LLC's 13F filing for Q2 2021, filed 13 Aug 2021.